IC
CLLS

Ikarian Capital’s Cellectis CLLS Stock Holding History

Ikarian Capital’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-73,067
Closed -$1.3M – 187
2020
Q2 		$1.3M Buy
73,067
+42,139
+136% +$641K 0.1% 116
2020
Q1 		$285K Buy
+30,928
New +$461K 0.02% 141

Other funds holding CLLS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Ikarian Capital's CLLS Position: Q3 2020 in Review

Ikarian Capital sold out of Cellectis (CLLS) in Q3 2020, closing a stake of 73,067 shares — an estimated $1.3M sold.

Ikarian Capital first reported a position in CLLS in Q1 2020 and held it in 2 quarters. The position peaked at $1.3M in Q2 2020. 74 funds tracked by Wall St. Rank hold CLLS as of Q3 2020.

  • Ikarian Capital reported no remaining Cellectis position as of Q3 2020 after selling out during the quarter.
  • Ikarian Capital sold 73,067 Cellectis shares in Q3 2020, an estimated $1.3M.
  • Ikarian Capital first reported a position in Cellectis in Q1 2020 and held it in 2 quarters.
  • Ikarian Capital's Cellectis position peaked at $1.3M in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Cellectis as of Q3 2020.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.